Anti-SARS-CoV-2 IgG Response after First and Second Dose of COVID-19 Vaccine
Background and objectives: Pandemics have serious adverse impacts on public health, economy, social structure, and overall growth and development of a nation. Such impacts can be mitigated by timely introduction of effective vaccination programs. This was successfully achieved in India. This study w...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Golestan University of Medical Sciences
2022-11-01
|
| Series: | Medical Laboratory Journal |
| Subjects: | |
| Online Access: | http://mlj.goums.ac.ir/article-1-1497-en.html |
| _version_ | 1797971536178577408 |
|---|---|
| author | Muragendraswami Astagimath Suman Doddamani Vishwanath Patil Raviraja Aryapu |
| author_facet | Muragendraswami Astagimath Suman Doddamani Vishwanath Patil Raviraja Aryapu |
| author_sort | Muragendraswami Astagimath |
| collection | DOAJ |
| description | Background and objectives: Pandemics have serious adverse impacts on public health, economy, social structure, and overall growth and development of a nation. Such impacts can be mitigated by timely introduction of effective vaccination programs. This was successfully achieved in India. This study was performed to compare the anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunoglobulin G (IgG) responses after first and second dose of coronavirus disease 2019 (COVID-19) vaccination.
Methods: This cross-sectional study included 60 people who were vaccinated with the AstraZeneca vaccine at Karnataka Institute of Medical Sciences, Hubballi, India. The subjects were divided into two groups. Group I included 30 people who had received a single dose of the vaccine, and group II included 30 people who had received two doses of the vaccine. Exclusion criteria included having a history of influenza like illness/severe acute respiratory infection/proven COVID-19 infection in past 6 months. The antibody response was measured by the Anti-SARS-CoV-2 IgG test using the VITROS Anti-SARS-CoV-2 IgG Reagent Pack.
Results: We observed that 97% of the subjects had reactive IgG antibodies after receiving two doses of the vaccine, whereas only 83% of the subjects developed antibodies after a single dose of the vaccine. A positive correlation was observed between the development of reactive antibodies and the duration between the first dose and the second dose (r=0.24).
Conclusion: Based on the results, the two-dose vaccination with the AstraZeneca vaccine is beneficial over the single-dose vaccination for protection against COVID-19. Moreover, increasing the duration between doses might improve the antibody response. |
| first_indexed | 2024-04-11T03:33:05Z |
| format | Article |
| id | doaj.art-1ca127a8b78a42b88d61caf51c6a8595 |
| institution | Directory Open Access Journal |
| issn | 2538-4449 |
| language | English |
| last_indexed | 2024-04-11T03:33:05Z |
| publishDate | 2022-11-01 |
| publisher | Golestan University of Medical Sciences |
| record_format | Article |
| series | Medical Laboratory Journal |
| spelling | doaj.art-1ca127a8b78a42b88d61caf51c6a85952023-01-02T05:45:43ZengGolestan University of Medical SciencesMedical Laboratory Journal2538-44492022-11-011664044Anti-SARS-CoV-2 IgG Response after First and Second Dose of COVID-19 VaccineMuragendraswami Astagimath0Suman Doddamani1Vishwanath Patil2Raviraja Aryapu3 Department of Biochemistry, Karnataka Institute of Medical Sciences, Hubballi, Karnataka, India Department of Biochemistry, Karnataka Institute of Medical Sciences, Hubballi Karnataka, India Assistant Professor,Department of General Medicine, Karnataka Institute of medical sciences, Hubballi, Karnataka, India. Department of General Medicine, Karnataka Institute of medical sciences, Hubballi, Karnataka, India Background and objectives: Pandemics have serious adverse impacts on public health, economy, social structure, and overall growth and development of a nation. Such impacts can be mitigated by timely introduction of effective vaccination programs. This was successfully achieved in India. This study was performed to compare the anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunoglobulin G (IgG) responses after first and second dose of coronavirus disease 2019 (COVID-19) vaccination. Methods: This cross-sectional study included 60 people who were vaccinated with the AstraZeneca vaccine at Karnataka Institute of Medical Sciences, Hubballi, India. The subjects were divided into two groups. Group I included 30 people who had received a single dose of the vaccine, and group II included 30 people who had received two doses of the vaccine. Exclusion criteria included having a history of influenza like illness/severe acute respiratory infection/proven COVID-19 infection in past 6 months. The antibody response was measured by the Anti-SARS-CoV-2 IgG test using the VITROS Anti-SARS-CoV-2 IgG Reagent Pack. Results: We observed that 97% of the subjects had reactive IgG antibodies after receiving two doses of the vaccine, whereas only 83% of the subjects developed antibodies after a single dose of the vaccine. A positive correlation was observed between the development of reactive antibodies and the duration between the first dose and the second dose (r=0.24). Conclusion: Based on the results, the two-dose vaccination with the AstraZeneca vaccine is beneficial over the single-dose vaccination for protection against COVID-19. Moreover, increasing the duration between doses might improve the antibody response.http://mlj.goums.ac.ir/article-1-1497-en.htmlcovid-19covid-19 vaccinespandemics |
| spellingShingle | Muragendraswami Astagimath Suman Doddamani Vishwanath Patil Raviraja Aryapu Anti-SARS-CoV-2 IgG Response after First and Second Dose of COVID-19 Vaccine Medical Laboratory Journal covid-19 covid-19 vaccines pandemics |
| title | Anti-SARS-CoV-2 IgG Response after First and Second Dose of COVID-19 Vaccine |
| title_full | Anti-SARS-CoV-2 IgG Response after First and Second Dose of COVID-19 Vaccine |
| title_fullStr | Anti-SARS-CoV-2 IgG Response after First and Second Dose of COVID-19 Vaccine |
| title_full_unstemmed | Anti-SARS-CoV-2 IgG Response after First and Second Dose of COVID-19 Vaccine |
| title_short | Anti-SARS-CoV-2 IgG Response after First and Second Dose of COVID-19 Vaccine |
| title_sort | anti sars cov 2 igg response after first and second dose of covid 19 vaccine |
| topic | covid-19 covid-19 vaccines pandemics |
| url | http://mlj.goums.ac.ir/article-1-1497-en.html |
| work_keys_str_mv | AT muragendraswamiastagimath antisarscov2iggresponseafterfirstandseconddoseofcovid19vaccine AT sumandoddamani antisarscov2iggresponseafterfirstandseconddoseofcovid19vaccine AT vishwanathpatil antisarscov2iggresponseafterfirstandseconddoseofcovid19vaccine AT ravirajaaryapu antisarscov2iggresponseafterfirstandseconddoseofcovid19vaccine |